Comparison of Circulating Tumour Cells and Circulating Cell-Free Epstein-Barr Virus DNA in Patients with Nasopharyngeal Carcinoma Undergoing Radiotherapy
暂无分享,去创建一个
Jackie Y Ying | Kam Weng Fong | J. Ying | M. Tan | L. Oon | K. Chan | K. Sommat | Y. Soong | K. Fong | S. Cheah | Min Hu | Shie Lee Cheah | Yoke Lim Soong | Wen Long Nei | Fuqiang Wang | Min-Han Tan | W. M. Phyo | H. Low | Kiattisa Sommat | Jess Honganh Vo | Wai Min Phyo | Terence Tan | Huiyu Low | Belinda Ling | Johnson Ng | Wan Loo Tan | Kian Sing Chan | Lynette Oon | J. Vo | W. Nei | Min Hu | W. Tan | Fuqiang Wang | J. Ng | T. Tan | Belinda Ling
[1] C. Almici,et al. Circulating tumour cells in locally advanced head and neck cancer: preliminary report about their possible role in predicting response to non-surgical treatment and survival. , 2012, European journal of cancer.
[2] W. Taylor,et al. Epstein-Barr virus-related antibody. Changes in titers after therapy for nasopharyngeal carcinoma. , 1990, Archives of otolaryngology--head & neck surgery.
[3] A. Theamboonlers,et al. Epstein-Barr viral DNA in serum of patients with nasopharyngeal carcinoma. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[4] F. O. Fackelmayer,et al. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. , 2001, Cancer research.
[5] A. King,et al. Early detection of nasopharyngeal carcinoma by plasma Epstein‐Barr virus DNA analysis in a surveillance program , 2013, Cancer.
[6] W. Taylor,et al. Antibody-dependent cellular cytotoxicity. Relation to stage and disease course in North American patients with nasopharyngeal carcinoma. , 1984, Archives of otolaryngology.
[7] S. Leung,et al. Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma. , 1999, Cancer research.
[8] T. Fehm,et al. Clinical application of circulating tumor cells in breast cancer: overview of the current interventional trials , 2012, Cancer and Metastasis Reviews.
[9] C. Punt,et al. Relationship among circulating tumor cells, CEA and overall survival in patients with metastatic colorectal cancer. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[10] A. Heath,et al. Collaborative Study to Evaluate the Proposed 1st WHO International Standard for Epstein-Barr Virus (EBV) for Nucleic Acid Amplification Technology (NAT)-Based Assays , 2011 .
[11] K. Chan,et al. Plasma Epstein-Barr virus DNA as a biomarker for nasopharyngeal carcinoma , 2014, Chinese journal of cancer.
[12] Mo Chao Huang,et al. Microsieve lab-chip device for rapid enumeration and fluorescence in situ hybridization of circulating tumor cells. , 2012, Lab on a chip.
[13] B. Lim,et al. Non‐invasive sensitive detection of KRAS and BRAF mutation in circulating tumor cells of colorectal cancer patients , 2015, Molecular oncology.
[14] K. Ang,et al. An International Collaboration to Harmonize the Quantitative Plasma Epstein-Barr Virus DNA Assay for Future Biomarker-Guided Trials in Nasopharyngeal Carcinoma , 2013, Clinical Cancer Research.
[15] S. Leung,et al. Plasma Epstein-Barr virus DNA and residual disease after radiotherapy for undifferentiated nasopharyngeal carcinoma. , 2002, Journal of the National Cancer Institute.
[16] S. Leung,et al. Molecular characterization of circulating EBV DNA in the plasma of nasopharyngeal carcinoma and lymphoma patients. , 2003, Cancer research.
[17] J. Zehnder,et al. A Comparison Study of Different PCR Assays in Measuring Circulating Plasma Epstein-Barr Virus DNA Levels in Patients with Nasopharyngeal Carcinoma , 2005, Clinical Cancer Research.
[18] M. Mar Albà,et al. Genome-Wide Analysis of Wild-Type Epstein–Barr Virus Genomes Derived from Healthy Individuals of the 1000 Genomes Project , 2014, Genome biology and evolution.
[19] N. Morgenthaler,et al. A novel method for the in vivo isolation of circulating tumor cells from peripheral blood of cancer patients using a functionalized and structured medical wire , 2012, International journal of oncology.
[20] W. Uen,et al. Development of an enzyme‐linked immunosorbent assay (ELISA) for detecting IgA antibodies to the epstein‐barr virus , 1988, International journal of cancer.
[21] S. Leung,et al. Plasma Epstein-Barr viral DNA load at midpoint of radiotherapy course predicts outcome in advanced-stage nasopharyngeal carcinoma. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[22] Caroline Dive,et al. Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] W. Taylor,et al. Antibodies to Epstein-Barr Virus in Patients with Nasopharyngeal Carcinoma and in Comparison Groups , 1984, The Annals of otology, rhinology, and laryngology.
[24] Stephen L. Chan,et al. Systemic treatment for inoperable pancreatic adenocarcinoma: review and update , 2014, Chinese journal of cancer.